Rising cost of raw materials a challenge for drug firms: Cipla’s Hamied
Published on 15 December, 2022 / Published by Business Standard

The pharma industry feels that 2023 will be about rising costs, patents and innovation. Samina Hamied, executive vice chairperson of Cipla and vice president of Indian Pharmaceutical Alliance (IPA), spoke to Sohini Das, about industry trends in 2022 and what is ahead.

Here are edited excerpts from an interview.

Covid-19 was a significant part of the domestic business of drug firms. Now that there are no Covid-19 sales how do firms calibrate their India strategies?

This article was originally published on Business Standard